MedPath

Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform

Completed
Conditions
Chronic Heart Failure
Interventions
Device: HeartWare Ventricular Assist Device
Registration Number
NCT03697980
Lead Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Brief Summary

Medtronic is sponsoring the Apogee study to further enhance scientific understanding of the implant procedure, optimized blood pressure management, and anticoagulation/ antiplatelet therapy in patients receiving a Medtronic HeartWare™ Ventricular Assist Device (HVAD™) for destination therapy.

The Apogee study is conducted within Medtronic's Product Surveillance Platform.

Detailed Description

The Apogee study is a prospective, observational, post-market, on-label, multi-site study in Destination Therapy patients. Patients participating in the Medtronic Destination Therapy (DT) Post Approval Study (PAS) (NCT03681210) are eligible for participation in Apogee. Patients enrolled in Apogee will be followed under the Apogee study for one-year post-implant. After participation in Apogee ends, patients will remain enrolled in DT PAS and will continue to be followed as outlined in the DT PAS protocol. The total estimated study duration is 33 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
136
Inclusion Criteria
  • Subjects consented to participate in DT PAS are eligible for participation in Apogee.
Exclusion Criteria
  • There are no exclusion criteria unique to Apogee.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
HVAD Left Ventricular Assist DeviceHeartWare Ventricular Assist DeviceDevice: HeartWare Ventricular Assist Device Other Names: HVAD The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Primary Outcome Measures
NameTimeMethod
Rate of Major Adverse EventsImplant to 12 months

Freedom from event is the probability (expressed as a percent of 100) the participant did not have a major adverse event during 12 months post implant via the Kaplan-Meier method. Participants that did not have a major adverse event were censored at the time of last follow-up in Apogee or their end of study at 12 months post implant, whichever occurred first.

Major adverse events are defined to be occurrence of infection, bleeding, device malfunction, CT confirmed stroke, or death. Infection, bleeding, device malfunction and CT confirmed stroke were categorized via Intermacs Version 5.0.

Events occurring during the implant procedure were excluded.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (33)

University of Washington Medical Center

🇺🇸

Seattle, Washington, United States

The Lindner Christ Hospital

🇺🇸

Cincinnati, Ohio, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Oklahoma Heart Institute

🇺🇸

Tulsa, Oklahoma, United States

University of California San Francisco Medical Center

🇺🇸

San Francisco, California, United States

Sentara Norfolk General Hospital

🇺🇸

Norfolk, Virginia, United States

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

University of Texas Health Sciences Center

🇺🇸

Houston, Texas, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Stanford University Hospital

🇺🇸

Stanford, California, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

University of Pittsburgh Medical Center UPMC Presbyterian

🇺🇸

Pittsburgh, Pennsylvania, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

The Ohio State University Wexner Medical Center

🇺🇸

Columbus, Ohio, United States

University of Texas Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

Houston Methodist Hospital

🇺🇸

Houston, Texas, United States

Cardiac Surgery Clinical Research Center

🇺🇸

Oak Lawn, Illinois, United States

The University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

The Johns Hopkins Hospital

🇺🇸

Baltimore, Maryland, United States

Columbia University

🇺🇸

New York, New York, United States

Virginia Commonwalth University Health System

🇺🇸

Richmond, Virginia, United States

AdventHealth

🇺🇸

Orlando, Florida, United States

Mayo Clinic Rochester

🇺🇸

Rochester, Minnesota, United States

University of Colorado

🇺🇸

Aurora, Colorado, United States

Providence St. Vincent Medical Center

🇺🇸

Portland, Oregon, United States

Saint Vincent Heart Clinic Arkansas

🇺🇸

Little Rock, Arkansas, United States

University of Louisville

🇺🇸

Louisville, Kentucky, United States

University of California San Diego

🇺🇸

San Diego, California, United States

NYU Langone Medical Center

🇺🇸

New York, New York, United States

University of Maryland Medical Center

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath